The use of anti-VEGF is rapidly becoming the standard of care for retinal vascular disease ... the treatment of ocular conditions with intravitreal injection. Bevacizumab is typically obtained ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

Intravitreal injections of anti-VEGF agents have become an important tool in the management of some of the most common retinal and choroidal neovascular diseases. Adverse effects are uncommon ...

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...

Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Increases in intraocular pressure have ...

ONS-5010 is an investigational ophthalmic formulation of bevacizumab, a vascular endothelial growth factor inhibitor (VEGF), under development as an intravitreal injection. Bevacizumab works by ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Susvimo is now available to U.S. retina specialists and their patients ... with those receiving monthly 0.5 mg ranibizumab intravitreal injections (9.6 eye chart letters, similar to gaining ...